Program
bempedoic acid
Also written as “ETC-1002”, “Bempedoic acid” and “180mg of ETC-1002(bempedoic acid)”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Hyperlipoproteinemia Type II, led by 6 companies.
Drug pageBempedoic acid: every studyMany companies study it; this page follows only the 33 they lead. All 43 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Esperion Therapeuticsits history only | 200 open or running | phase 4since Aug 27, 2023 | Dec 16, 2010 | none ahead |
| Daiichi Sankyo | 61 open or running | phase 4since Apr 6, 2025 | Apr 6, 2025 | Jun 1, 2028phase 3 · NCT07474649 |
| Otsukaits history only | 30 open or running | phase 3since Jan 4, 2023 | Mar 2, 2021 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 20 open or running | phase 1since Apr 4, 2025 | Apr 4, 2025 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 3since May 29, 2026 | May 29, 2026 | Jun 30, 2027phase 3 · NCT07623915 |
| Gan & Lee Pharmaceuticalsits history only | 10 open or running | phase 3since Jan 13, 2025 | Jan 13, 2025 | none ahead |
Also a collaborator on its studies: Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Daiichi Sankyo only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 6, 2025First study: phase 4 study in Hyperlipoproteinemia Type IIFirst studyNCT06925100 · 180 enrolled · Taiwan
- Sep 11, 20252 phase 1 studies in Healthy SubjectsNCT07182383, NCT07201545
- Nov 14, 20252 phase 1 studies in Healthy SubjectsNCT07235189, NCT07268625
- Mar 11, 2026Phase 3 study in Coronary Artery DiseaseNCT07474649 · 103 planned · Germany, Italy, Spain
Ahead
- Jun 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseNCT07474649
TargetBeta
“An orally bioavailable prodrug and inhibitor of adenosine triphosphate-citrate lyase (ACL), with anti-hyperlipidemic activity”NCIt, by rule
“ATP-citrate synthase inhibitor”ChEMBL 37, by rule
Studies
All 6 Daiichi Sankyo leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07474649Coronary Artery Disease · Germany, Italy, Spain | 3 | Recruiting | Jun 1, 2028 | 103 |
| NCT07268625Healthy Subjects · Portugal | 1 | Completed | Feb 24, 2026 | 58 |
| NCT07235189Healthy Subjects · Portugal | 1 | Completed | Jan 28, 2026 | 58 |
| NCT07201545Healthy Subjects · Portugal | 1 | Completed | Dec 10, 2025 | 58 |
| NCT07182383Healthy Subjects · Portugal | 1 | Completed | Nov 24, 2025 | 58 |
| NCT06925100Hyperlipoproteinemia Type II · Taiwan | 4 | Completed | Oct 15, 2025 | 180 |
How it is read
Names in the registry
- “ETC-1002”, 10 entries
- “Bempedoic acid”, 7 entries
- “180mg of ETC-1002(bempedoic acid)”, 3 entries
- “bempedoic acid”, 3 entries
- “Bempedoic Acid Tablet”, 2 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 16 studies
- Hyperlipidemias, 5 studies
- Dyslipidemias, 2 studies
- Coronary Artery Disease, 1 study
- Hyperlipoproteinemia Type II, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.